Combining Epigenetic and Immunotherapy to Combat Cancer

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• Immunotherapy, particularly immune checkpoint blockade, is a significant advance in cancer management.
• Most patients with advanced cancers, excluding melanoma, show limited response to immunotherapy alone.
• Epigenetic drugs, such as DNA methyltransferase inhibitors, can enhance anti-tumor immune responses.

Purpose of the Study:

• To investigate the potential of epigenetic drugs to improve immunotherapy efficacy in epithelial cancers.
• To explore the mechanisms by which DNA methyltransferase inhibitors modulate immune signaling in cancer cells.

Main Methods:

• Utilized DNA methyltransferase inhibitors to demethylate endogenous retroviruses and cancer testis antigens in epithelial cancer cells.
• Assessed the impact of these epigenetic modifications on immune signaling pathways.
• Evaluated the combination therapy of demethylating agents and immune checkpoint inhibitors in mouse models.

Main Results:

• Demethylation by epigenetic drugs upregulated immune signaling in epithelial cancer cells.
• These agents were shown to induce T-cell attraction.
• Combination therapy demonstrated enhanced efficacy in preclinical mouse models.

Conclusions:

• Epigenetic drugs can sensitize epithelial cancers to immunotherapy by enhancing immune signaling.
• The combination of epigenetic drugs and immune checkpoint inhibitors represents a promising new strategy for durable cancer management.
• Further clinical trials are warranted to validate this combination therapy in human patients.